Cargando…
Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells
INTRODUCTION: Cancer stem cells (CSCs) drive the initiation, maintenance, and therapy response of breast tumors. CD49f is expressed in breast CSCs and functions in the maintenance of stemness. Thus, blockade of CD49f is a potential therapeutic approach for targeting breast CSCs. In the present stu...
Autores principales: | Velázquez-Quesada, Inés, Ruiz-Moreno, Angel J, Casique-Aguirre, Diana, Aguirre-Alvarado, Charmina, Cortés-Mendoza, Fabiola, de la Fuente-Granada, Marisol, García-Pérez, Carlos, Pérez-Tapia, Sonia M, González-Arenas, Aliesha, Segura-Cabrera, Aldo, Velasco-Velázquez, Marco A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229803/ https://www.ncbi.nlm.nih.gov/pubmed/32494122 http://dx.doi.org/10.2147/DDDT.S247730 |
Ejemplares similares
-
Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications
por: Valdés-Rives, Silvia Anahi, et al.
Publicado: (2017) -
Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells
por: Aguirre-Alvarado, Charmina, et al.
Publicado: (2016) -
Progesterone Receptor Together with PKCα Expression as Prognostic Factors for Astrocytomas Malignancy
por: Arcos-Montoya, Denisse, et al.
Publicado: (2021) -
Metabolite Dysregulation by Pranlukast in Mycobacterium tuberculosis
por: Yelamanchi, Soujanya D., et al.
Publicado: (2022) -
Efficacy and Safety of Modified Pranlukast (Prakanon(®)) Compared with Pranlukast (Onon(®)): A Randomized, Open-Label, Crossover Study
por: Kim, Seo W., et al.
Publicado: (2016)